Novartis blockbuster mAb Cosentyx EU re two new indications!...

Swiss pharmaceutical giant Novartis (Novartis) immune pipeline industry has been concerned blockbuster monoclonal antibody drugs Cosentyx (secukimumab) harvested in the United States and Europe at the same time two major markets plaque psoriasis (plaque psoriasis) indications, the company Drug regulation in 2015 ushered in the opener. And just recently, Cosentyx EU regulation came big news again, this medicine while harvesting ankylosing spondylitis (ankylosing spondylitis, AS) and psoriatic arthritis (psoriatic arthritis, PsA) two indications.
Cosentyx is the first global interleukin-17 (IL-17) monoclonal antibody, the ratification marks the Cosentyx become IL-17 monoclonal antibody drugs in the first and only one in Europe to treat the two most common inflammatory joint diseases, but also it marks the Cosentyx become the first new treatment breakthroughs following anti-TNF monoclonal antibody drugs for 16 years after the listing of AS clinical regard.
According to recently published data, Cosentyx in 1-3 weeks of treatment can significantly improve the AS or PsA signs and symptoms, and this improvement can be sustained for more than 2 years. AS aspect, Cosentyx patients receiving treatment, up to 80% at 2 years after the adoption of X-ray inspection showed no progress in spinal cord injury; PsA regard Cosentyx patients receiving treatment, up to 84% at 2 years after the adoption of X-ray inspection showed no joint damage progression.
Currently, in clinical trials across multiple indications aspects, there are more than 9600 cases of patients received Cosentyx treatment; there are more than 12,500 cases of patients underwent post-marketing studies Cosentyx treatment. Safety, Cosentyx consistent performance in clinical research across multiple indications in.
Specifically, AS aspect, Cosentyx EU approved for adult patients with AS conventional therapies (such as non-steroidal anti-inflammatory drugs) inadequate response; PsA aspect, Cosentyx EU approved as a single agent or in combination with methotrexate (methotrexate) for the previous disease-modifying anti-rheumatic drug reactions against inadequate PsA in adult patients.
In addition, Novartis is also actively promoting other relevant clinical program Cosentyx, and expanding the potential indications for the drug. Cosentyx of the industry is very optimistic about business prospects, expected annual sales of the drug to 2020 will exceed $ 1 billion, becoming the IL-17 mAb heavy field a shining star.
However, the other competitors in the field are quickly follow, such as Lilly's IL-17 mAb ixekizumab in a number of Phase III clinical also set a remarkable achievement.
Another noteworthy event was the British pharmaceutical giant AstraZeneca has also been high hopes for the industry before the IL-17 mAb brodalumab, but brodalumab patients treated in clinical trials observed suicidal tendencies, Amgen select AstraZeneca parted ways; and AstraZeneca chose to give up more than three months after reflection after brodalumab price of $ 445 million will be packaged for sale to Valeant Pharmaceuticals, the event is also the industry that AstraZeneca in inflammatory diseases A flaw field.